Oncology

CDK4

CHEMBL331

ACCUMULATING

Selectivity-first: 16,735 compounds with predicted CDK4/CDK6 selectivity > 20x. Aims to address neutropenia-limited dose ceilings.

ADMET Passed

16,735

Pareto Rank 1

812

CRO

Awaiting CRO decision

Stage

Accumulating

Mechanism

Selective CDK4 inhibition — avoid CDK6-driven neutropenia observed with palbociclib.

Precedent

Palbociclib (Pfizer), Ribociclib (Novartis), Abemaciclib (Lilly) — all pan-CDK4/6.

Indications

HR+/HER2- breast cancer · Melanoma

Milestones

2026-W11

16,735 candidates accumulated with CDK4 > CDK6 selectivity

2026-W14

Top-10 selected for ABFE physics validation

2026-W16

CRO submission decision expected